Digital breast tomosynthesis (DBT) equipment provides improved detection and diagnosis of breast cancer over conventional 2D mammography. DBT equipment captures multiple low-dose x-ray images of the breast from different angles and uses advanced computer algorithms to construct 3D-like images of the breast tissue. This enables physicians to better visualize small abnormalities and distinguish tumors from overlying tissues. The advanced imaging capabilities of DBT equipment have significantly improved early cancer detection rates. The global demand for DBT equipment is rising due to the increasing prevalence of breast cancer worldwide and growing awareness about the clinical benefits of 3D mammography over conventional 2D tests.
The Global Digital Breast Tomosynthesis Equipment Market is estimated to be valued at US$ 975 million in 2024 and is expected to exhibit a CAGR of 15% over the forecast period 2024 to 2031.
Key Takeaways
- Key players operating in the digital breast tomosynthesis equipment market are Hologic Inc., Fujifilm Corporation, General Electric Company, Siemens Healthineers AG, and Koninklijke Philips N.V.
- Growing public-private investments to modernize breast cancer screening programs in developing countries provide lucrative opportunities for market players.
- Advancements such as contrast-enhanced spectral mammography, artificial intelligence-assisted image analysis, and cloud-based digital breast tomosynthesis solutions are enhancing the clinical efficacy and accessibility of 3D mammography.
Market Drivers
The rising geriatric population and the associated risk of breast cancer coupled with growing awareness about the benefits of DBT for early cancer detection are major market drivers. Government initiatives to promote breast cancer screening and expanding healthcare insurance coverage for breast cancer diagnosis are further fueling the adoption of DBT equipment worldwide.
Challenges in Digital Breast Tomosynthesis Equipment Market
The digital breast tomosynthesis equipment market is facing challenges related to high costs of equipment and installation. As DBT systems are complex machines requiring extensive technical expertise, their installation and maintenance costs are quite high. This poses a significant challenge for small hospitals and clinics to invest in such advanced medical imaging technologies. Another challenge is the lack of adequate clinical evidence on the efficacy and accuracy of DBT compared to conventional mammography. More research studies need to be conducted to quantify the benefits of DBT in terms of early cancer detection rates and reduce call-back rates. Limited reimbursement policies for new medical technologies also restrain widespread adoption of DBT systems.
Current Challenges in the Digital Breast Tomosynthesis Equipment Market
One of the key challenges currently faced by players in the digital breast tomosynthesis equipment market is limited clinical evidence supporting the superior diagnostic accuracy of DBT over digital mammography. While several studies have demonstrated DBT's potential, extensive clinical research and real-world evidence is still needed regarding its impact on clinical outcomes. This lack of definitive clinical validation poses adoption challenges. Another major hurdle is the high costs associated with DBT systems and upgrades. As DBT devices are complex, specialized pieces of medical imaging equipment, their prices are significantly higher than conventional mammography units. This financial barrier limits procurements, especially for budget-strapped hospitals and diagnostic centers in developing regions. Limited reimbursement coverage for DBT by both public and private payers also restricts widespread commercialization of this novel breast cancer screening technology.
SWOT Analysis
Strength: Advanced 3D imaging technique provides improved visualization of breast tissue and increased cancer detection rates. Weakness: Systems are significantly more expensive than conventional mammography equipment. Opportunity: Growing awareness about benefits of DBT in comparison to mammograms will boost replacement/adjunct purchases. Threats: Lack of definitive clinical validation and uncertain reimbursement policies currently pose threats to market potential.
In terms of value, North America accounts for the major share in digital breast tomosynthesis equipment market owing to developed healthcare infrastructure, rising healthcare spending, and growing incidences of breast cancer. Asia Pacific is poised to witness the fastest growth during the forecast period driven by increasing awareness regarding early cancer detection, growing healthcare expenditure, and improving medical technologies acceptance in some regional countries like China and India. The Middle East & Africa region is also emerging as a lucrative market landscape with growing government focus on strengthening healthcare systems. Latin America market is projected to expand steadily as breast cancer diagnosis becomes a more prominent public health issue in the region.
The North American region currently dominates the digital breast tomosynthesis equipment market in terms of value largely due to advanced healthcare infrastructure, rising healthcare spending, availability of skilled medical professionals, and growing breast cancer incidence. The Asia Pacific market is anticipated to witness the highest growth during the forecast period. Improving access to medical facilities, rising healthcare expenditures, growing public health awareness regarding early breast cancer detection in countries like China and India are some key factors driving the APAC digital breast tomosynthesis market growth.
Get this Report in Japanese Language: デジタル乳房トモシンセシス装置市場
Get this Report in Korean Language: ぢ 기타 l B 희귀 st 모두 syn s s
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
